Immunotherapy has revolutionized cancer treatment. However, a significant proportion of patients still do not respond effectively. In our lab, we delve into cancer immunology, leveraging our expertise in protein engineering, molecular biology, and immunology. Our primary focus is unraveling the intricate mechanisms underlying the dynamic changes in the tumor microenvironment triggered by cancer immunotherapies. Through our research, we aim to develop innovative diagnostic, prognostic, and therapeutic tools that enable precise detection, characterization, treatment, and prevention of cancer.
Enhancing the activity and persistence of CAR T cells is a key area of investigation in our lab. CAR T cells have revolutionized the treatment of various blood-borne malignancies. However, the duration of response often falls short, leading to patient relapse. To address this challenge, we are developing novel immunotherapeutics to drive CAR T cells toward adopting a memory phenotype. This approach holds great potential in prolonging the response duration and overcoming relapse.